Vivozon Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Vivozon Pharmaceutical makes finished medicines, including treatments for circulatory conditions, diabetes, fever and pain relief, skin conditions, and influenza, supplied to patients through prescription and over-the-counter channels in Korea.
It is listed on KOSDAQ, Korea's tech and small-cap exchange. Beyond its own branded products, the company also operates contract manufacturing and private-label production businesses, giving it multiple revenue streams across its portfolio of well over a hundred product lines.
Summary is AI-generated and may contain errors · figures from DART filings
Vivozon Pharmaceutical in five facts
What does Vivozon Pharmaceutical do?
Vivozon Pharmaceutical makes finished medicines, including treatments for circulatory conditions, diabetes, fever and pain relief, skin conditions, and influenza, supplied to patients through prescription and over-the-counter channels in Korea.
Where is Vivozon Pharmaceutical listed and in which sector?
Vivozon Pharmaceutical (Korean name: 비보존 제약) trades under KRX code 082800 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Vivozon Pharmaceutical?
Its market capitalisation was US$141.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Vivozon Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, Vivozon Pharmaceutical reported revenue of US$44.8M, an operating loss of US$14.5M and a net loss of US$24.5M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 32.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Conversion price adjustmentOct 12
- Report on large shareholdings (5% rule) (standard)Oct 6
- Report on large shareholdings (5% rule) (standard)Sep 22
- Early redemption of convertible bonds (incl. overseas CBs)
Vivozon Pharmaceutical Co., Ltd. acquired US$1.76M in face value of its Series 15 private-placement convertible bonds (conversion price US$6.34/share, maturing 2028-01-31) on 2026-07-31 for US$2.03M including early-redemption interest, following the bondholder's exercise of its put option, leaving US$8.8M outstanding; the acquired bonds will be retired.
Capital raise · Jul 31 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Apr 30
- Treasury share disposal: results reportTreasury Shares · Apr 15
- Material event report (treasury share disposal)
Vivozon Pharmaceutical disclosed a plan to sell treasury shares worth US$391K, about 0.3% of its market value.
Treasury Shares · Apr 10 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Mar 31
- Subscription results of rights offering or equity-linked bonds (voluntary) (rights offering with public offering of forfeited shares)Capital raise · Feb 25
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Vivozon Pharmaceutical reported consolidated results for FY2025: revenue of US$41M (−32.26% year on year), an operating loss of US$13.1M (from a profit a year earlier) and a net loss of US$22.3M.
Earnings · Feb 20 - Rights offering: final issue price set (rights offering with public offering of forfeited shares)Capital raise · Feb 19
- [Amended] Material event report (rights offering)
Vivozon Pharmaceutical updated the terms of a new share issuance to raise US$22.6M, about 17.6% of its market value.
Capital raise · Feb 19 - [Amended] Material event report (convertible bonds)Capital raise · Jan 23
- Ex-rights (rights offering)Capital raise · Jan 8
- Rights offering: round 1 issue price setCapital raise · Jan 8
- [Amended] Material event report (rights offering)Capital raise · Jan 8